Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PRECISION BIOSCIENCES, INC.

(DTIL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Precision BioSciences : Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635(c)(4)

09/27/2021 | 11:11am EST

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced an inducement grant for Michael Amoroso, newly appointed President and Chief Executive Officer of Precision BioSciences.

The Compensation Committee of the Company’s Board of Directors has granted to Mr. Amoroso, effective with his commencement of employment (the “grant date”), inducement awards composed of an option to purchase (the “stock option”) 850,000 shares of the Company’s common stock (the “option award”) and restricted stock units (“RSUs”) representing a number of shares of the Company’s common stock having a grant date fair value of $237,000 (the “RSU award”).

The stock option has a per share exercise price equal to the fair market value of the Company’s common stock on the grant date, a 10-year term and vests (subject to Mr. Amoroso’s continued service to the Company through the applicable vesting dates) as to 25% of the award on October 15, 2022 and, as to the remaining 75%, in substantially equal quarterly installments over the three years thereafter. The RSU award covers a number of shares of the Company’s common stock having a grant date fair value of $237,000 divided by the closing price of the Company’s common stock on the grant date. The RSUs vest in full (subject to Mr. Amoroso’s continued service to the Company) on October 15, 2022.

Each of the stock option and the RSU grant were granted pursuant to the Company’s 2021 Employment Inducement Incentive Award Plan and were approved by the Company’s Compensation Committee. Each of the option award and the RSU award were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to Mr. Amoroso’s entering into employment with the Company.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene editing candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.


© Business Wire 2021
All news about PRECISION BIOSCIENCES, INC.
12/06Precision BioSciences to Host Virtual Webcast and Conference Call to Review Interim Pha..
BU
12/03Precision BioSciences to Present Preclinical Gene Editing Data on Hepatitis B Program D..
MT
12/03Precision BioSciences to Present Preclinical Gene Editing Data on its ARCUS-Based Chron..
BU
11/10Precision BioSciences' Q3 Loss Narrows, Revenue Improves
MT
11/10PRECISION BIOSCIENCES INC Management's Discussion and Analysis of Financial Condition ..
AQ
11/10Precision BioSciences Reports Third Quarter 2021 Financial Results and Provides Busines..
PU
11/10PRECISION BIOSCIENCES : Q3 Earnings Snapshot
AQ
11/10Precision BioSciences Reports Third Quarter 2021 Financial Results and Provides Busines..
BU
11/10Earnings Flash (DTIL) PRECISION BIOSCIENCES Reports Q3 Revenue $24M
MT
11/10NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
More news
Analyst Recommendations on PRECISION BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 114 M - -
Net income 2021 -38,8 M - -
Net cash 2021 136 M - -
P/E ratio 2021 -14,6x
Yield 2021 -
Capitalization 539 M 539 M -
EV / Sales 2021 3,54x
EV / Sales 2022 10,6x
Nbr of Employees 226
Free-Float 88,1%
Chart PRECISION BIOSCIENCES, INC.
Duration : Period :
Precision BioSciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PRECISION BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 8,87 $
Average target price 16,29 $
Spread / Average Target 83,6%
EPS Revisions
Managers and Directors
Michael Amoroso President, Chief Executive Officer & Director
John Alexander Kelly Chief Financial & Corporate Affairs Officer
Kevin J. Buehler Chairman
Jeff Smith Chief Technology Officer
Derek N. Jantz Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
PRECISION BIOSCIENCES, INC.-0.96%502
MODERNA, INC.153.98%107 578
LONZA GROUP AG25.98%56 683
IQVIA HOLDINGS INC.46.84%50 262
SEAGEN INC.-16.63%26 699
CELLTRION, INC.-43.31%23 888